WallStSmart

Lucid Diagnostics Inc (LUCD)vsStryker Corporation (SYK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 474409% more annual revenue ($25.84B vs $5.45M). SYK leads profitability with a 14.4% profit margin vs 0.0%. SYK earns a higher WallStSmart Score of 67/100 (B-).

LUCD

Avoid

24

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 5.0Quality: 3.5
Piotroski: 4/9Altman Z: -13.63

SYK

Strong Buy

67

out of 100

Grade: B-

Growth: 8.0Profit: 8.0Value: 4.7Quality: 6.5
Piotroski: 2/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LUCD.

SYKSignificantly Overvalued (-23.0%)

Margin of Safety

-23.0%

Fair Value

$229.79

Current Price

$282.55

$52.76 premium

UndervaluedFair: $229.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LUCD1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
26.7%8/10

Revenue surging 26.7% year-over-year

SYK4 strengths · Avg: 8.3/10
Market CapQuality
$106.71B9/10

Large-cap with strong market position

Operating MarginProfitability
27.0%8/10

Strong operational efficiency at 27.0%

EPS GrowthGrowth
44.1%8/10

Earnings expanding 44.1% YoY

Free Cash FlowQuality
$1.06B8/10

Generating 1.1B in free cash flow

Areas to Watch

LUCD4 concerns · Avg: 3.5/10
Price/BookValuation
9.1x4/10

Trading at 9.1x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$121.83M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

SYK2 concerns · Avg: 3.5/10
P/E RatioValuation
28.8x4/10

Moderate valuation

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : LUCD

The strongest argument for LUCD centers on Revenue Growth. Revenue growth of 26.7% demonstrates continued momentum.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap, Operating Margin, EPS Growth. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bear Case : LUCD

The primary concerns for LUCD are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 2.28 is elevated, increasing financial risk.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

LUCD profiles as a growth stock while SYK is a value play — different risk/reward profiles.

LUCD carries more volatility with a beta of 1.12 — expect wider price swings.

LUCD is growing revenue faster at 26.7% — sustainability is the question.

SYK generates stronger free cash flow (1.1B), providing more financial flexibility.

Bottom Line

SYK scores higher overall (67/100 vs 24/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lucid Diagnostics Inc

HEALTHCARE · MEDICAL DEVICES · USA

Lucid Diagnostics Inc. is a commercial stage medical diagnostic technology company. The company is headquartered in New York, New York.

Visit Website →

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?